Source of Peptide harm reduction

{{Infobox concept | name = Peptide harm reduction | subtitle = Harm reduction | Principle = Reduce harm without requiring abstinence | Applied to = Material of uncertain identity, content and sterility | Limit = Information is not a substitute for regulated supply }} '''Peptide harm reduction''' applies harm-reduction principles — reducing harm among people engaged in a practice, without requiring that they stop — to the situation of people obtaining peptides outside regulated supply.{{r|marlatt1996}} The uncertainties are specific and documented elsewhere on this wiki: identity, which a purity figure does not establish; content, which determines how much active substance a vial holds; sterility, which a research-chemical powder does not have; and provenance, which determines whether any document attaches to the material at all.{{r|usp1503}} This wiki's contribution to harm reduction is documentary: explaining what a determination establishes and what it does not, so that a reader can tell an informative document from an uninformative one. It does not advise on use, and research-use compounds are not approved for human administration.{{r|reports}} == What the uncertainties are == | Uncertainty | Resolved by | Commonly reported? | |---|---|---| | Identity | [[Mass spectrometry]] confirmation | Sometimes | | Purity | Named chromatographic method | Usually | | Content | [[Peptide content]], water, counterion | Rarely | | Fill mass | Gravimetric check | Rarely | | Sterility | [[Sterility testing]]; not applicable to research powders | No | | Endotoxin | [[Bacterial endotoxin test]] | Rarely | | Provenance | [[Lot traceability]] records | Variable | The row that matters most and is reported least is content. Without it the mass of peptide in a vial is unknown, and every downstream quantity — concentration after [[Reconstitution of lyophilised peptides|reconstitution]], volume drawn, exposure — inherits that unknown.{{r|usp1503}} The sterility row is categorical rather than probabilistic: a lyophilised research powder is not manufactured as a sterile product, so the question is not how likely it is to be sterile but that it is not represented as being so.{{r|usp1503}} == What documentation can and cannot fix == A complete document set narrows the identity, purity and content uncertainties substantially. It does not address sterility, does not establish that the vial in hand came from the lot described, and does not make an unapproved compound an approved one.{{r|reports}} [[Third-party testing|Independent testing]] narrows them further for the sample tested, subject to the sampling and custody limitations set out at [[Blind sampling]] and [[Chain of custody]]. What no document addresses is the absence of clinical oversight — no diagnosis, no monitoring, no clinician aware of the exposure if something goes wrong, and no adverse-event reporting route.{{r|ada2024}} That is a structural feature of unregulated supply rather than a documentation gap. See [[Aspiration risk under anaesthesia]] for one concrete instance.{{r|marlatt1996}} == The limits of this article == Harm reduction as a field distinguishes providing information from encouraging a practice. This wiki provides information about documents, methods and compounds, and takes no position on whether anyone should obtain material outside regulated supply.{{r|marlatt1996}} It gives no dosing guidance, describes no preparation intended for administration, and does not evaluate suppliers for suitability. Where handling is described — at [[Reconstitution of lyophilised peptides]], for instance — it is described mechanistically, and the register is deliberately descriptive. Nothing on this wiki is medical advice. Research-use compounds are not approved for human use, and this article does not represent them as suitable for it.{{r|usp1503}} == References == {{reflist}} <ref name="marlatt1996">Marlatt GA. "Harm reduction: come as you are." ''Addictive Behaviors'' 21(6):779–788 (1996). PMID 8904943.</ref> <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> == See also == * [[Research use only]] * [[Certificate of analysis]] * [[Peptide content]] * [[Third-party testing]] * [[Global access disparity]] * [[Reconstitution of lyophilised peptides]] {{DEFAULTSORT:Peptide harm reduction}} [[Category:Harm reduction]] [[Category:Access and economics]] [[Category:Quality and testing]]